308 related articles for article (PubMed ID: 27620852)
1. Barriers to HIV Cure.
Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
[TBL] [Abstract][Full Text] [Related]
2. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
4. The development of immune-modulating compounds to disrupt HIV latency.
Remoli AL; Marsili G; Battistini A; Sgarbanti M
Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
[TBL] [Abstract][Full Text] [Related]
6. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
7. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
Suryawanshi P; Bagul R; Shete A; Thakar M
Front Immunol; 2021; 12():663919. PubMed ID: 33995393
[TBL] [Abstract][Full Text] [Related]
8. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
9. The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.
Vandergeeten C; Fromentin R; Chomont N
Cytokine Growth Factor Rev; 2012; 23(4-5):143-9. PubMed ID: 22743037
[TBL] [Abstract][Full Text] [Related]
10. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
Pohlmeyer CW; Walker-Sperling VE; Blankson JN
Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
[No Abstract] [Full Text] [Related]
11. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
12. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.
Shan L; Siliciano RF
Bioessays; 2013 Jun; 35(6):544-52. PubMed ID: 23613347
[TBL] [Abstract][Full Text] [Related]
13. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS.
North TW; Higgins J; Deere JD; Hayes TL; Villalobos A; Adamson L; Shacklett BL; Schinazi RF; Luciw PA
J Virol; 2010 Mar; 84(6):2913-22. PubMed ID: 20032180
[TBL] [Abstract][Full Text] [Related]
14. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
Forde J; Volpe JM; Ciupe SM
Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
[TBL] [Abstract][Full Text] [Related]
15. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
16. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
17. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
18. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
Sedaghat AR; Siliciano JD; Brennan TP; Wilke CO; Siliciano RF
PLoS Pathog; 2007 Aug; 3(8):e122. PubMed ID: 17784786
[TBL] [Abstract][Full Text] [Related]
19. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
20. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]